Literature DB >> 25479742

Pushing the limits: defeating leukemia stem cells by depleting telomerase.

Ya-Huei Kuo1, Ravi Bhatia2.   

Abstract

Leukemia stem cells (LSCs), featuring unlimited self-renewal capacity and chemoresistance, are critical cellular targets for new treatments to improve outcomes for acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Bruedigam et al. (2014) demonstrate that inhibition of telomerase is damaging to LSCs and may represent a promising therapeutic approach in AML.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25479742      PMCID： PMC4394378          DOI： 10.1016/j.stem.2014.11.014

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  8 in total

Review 1.  Bone marrow failure and the telomeropathies.

Authors:  Danielle M Townsley; Bogdan Dumitriu; Neal S Young
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

Review 2.  Transcriptional outcome of telomere signalling.

Authors:  Jing Ye; Valérie M Renault; Karine Jamet; Eric Gilson
Journal:  Nat Rev Genet       Date:  2014-06-10       Impact factor: 53.242

3.  Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.

Authors:  A Gessner; M Thomas; P Garrido Castro; L Büchler; A Scholz; T H Brümmendorf; N Martinez Soria; J Vormoor; J Greil; O Heidenreich
Journal:  Leukemia       Date:  2010-08-05       Impact factor: 11.528

4.  Telomerase stimulates ribosomal DNA transcription under hyperproliferative conditions.

Authors:  Omar Garcia Gonzalez; Robin Assfalg; Sylvia Koch; Adrian Schelling; Jitendra K Meena; Johann Kraus; Andre Lechel; Sarah-Fee Katz; Vladimir Benes; Karin Scharffetter-Kochanek; Hans A Kestler; Cagatay Günes; Sebastian Iben
Journal:  Nat Commun       Date:  2014-08-13       Impact factor: 14.919

5.  Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.

Authors:  Brittney-Shea Herbert; Ginelle C Gellert; Amelia Hochreiter; Krisztina Pongracz; Woodring E Wright; Daria Zielinska; Allison C Chin; Calvin B Harley; Jerry W Shay; Sergei M Gryaznov
Journal:  Oncogene       Date:  2005-08-04       Impact factor: 9.867

6.  Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.

Authors:  Claudia Bruedigam; Frederik O Bagger; Florian H Heidel; Catherine Paine Kuhn; Solene Guignes; Axia Song; Rebecca Austin; Therese Vu; Erwin Lee; Sarbjit Riyat; Andrew S Moore; Richard B Lock; Lars Bullinger; Geoffrey R Hill; Scott A Armstrong; David A Williams; Steven W Lane
Journal:  Cell Stem Cell       Date:  2014-12-04       Impact factor: 24.633

7.  Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice.

Authors:  Carolina Vicente-Dueñas; Marcos Barajas-Diego; Isabel Romero-Camarero; Inés González-Herrero; Teresa Flores; Isidro Sánchez-García
Journal:  Oncotarget       Date:  2012-03

8.  Short telomeres in ESCs lead to unstable differentiation.

Authors:  Fabio Pucci; Laura Gardano; Lea Harrington
Journal:  Cell Stem Cell       Date:  2013-04-04       Impact factor: 24.633
  8 in total
  2 in total

Review 1.  The biomarkers of leukemia stem cells in acute myeloid leukemia.

Authors:  Yahui Ding; Huier Gao; Quan Zhang
Journal:  Stem Cell Investig       Date:  2017-03-02

Review 2.  The Historical Relationship Between Meis1 and Leukemia.

Authors:  Neslihan Meriç; Fatih Kocabaş
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.